Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADMA NASDAQ:AUTL NASDAQ:GRTS NASDAQ:NK NASDAQ:STRO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADMAADMA Biologics$8.69+1.4%$9.05$7.21▼$20.46$2.01B0.725.13 million shs2.99 million shsAUTLAutolus Therapeutics$1.66+11.4%$1.58$1.18▼$2.70$441.82M2.021.69 million shs1.56 million shsGRTSGritstone bio$0.03$0.35$0.03▼$3.17$3.50M0.497.01 million shsN/ANKNantKwest$6.98+1.7%$28.01$2.52▼$45.42$763.23M2.611.57 million shs16.54 million shsSTROSutro Biopharma$29.19-7.5%$31.53$6.74▼$43.85$483.68M1.54216,847 shs226,884 shsThe 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADMAADMA Biologics+3.13%+0.82%+4.00%-24.36%-51.69%AUTLAutolus Therapeutics-1.32%-0.67%-12.35%+12.88%-27.32%GRTSGritstone bio0.00%0.00%0.00%0.00%0.00%NKNantKwest0.00%0.00%0.00%-25.74%+143.21%STROSutro Biopharma+6.48%+4.47%+23.39%+33.86%+293.93%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADMAADMA Biologics$8.69+1.4%$9.05$7.21▼$20.46$2.01B0.725.13 million shs2.99 million shsAUTLAutolus Therapeutics$1.66+11.4%$1.58$1.18▼$2.70$441.82M2.021.69 million shs1.56 million shsGRTSGritstone bio$0.03$0.35$0.03▼$3.17$3.50M0.497.01 million shsN/ANKNantKwest$6.98+1.7%$28.01$2.52▼$45.42$763.23M2.611.57 million shs16.54 million shsSTROSutro Biopharma$29.19-7.5%$31.53$6.74▼$43.85$483.68M1.54216,847 shs226,884 shsThe 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADMAADMA Biologics+3.13%+0.82%+4.00%-24.36%-51.69%AUTLAutolus Therapeutics-1.32%-0.67%-12.35%+12.88%-27.32%GRTSGritstone bio0.00%0.00%0.00%0.00%0.00%NKNantKwest0.00%0.00%0.00%-25.74%+143.21%STROSutro Biopharma+6.48%+4.47%+23.39%+33.86%+293.93%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADMAADMA Biologics 2.33Hold$19.67126.31% UpsideAUTLAutolus Therapeutics 2.89Moderate Buy$8.75427.11% UpsideGRTSGritstone bio 0.00N/AN/AN/ANKNantKwest 0.00N/AN/AN/ASTROSutro Biopharma 2.92Moderate Buy$52.4479.67% UpsideCurrent Analyst Ratings BreakdownLatest STRO, GRTS, AUTL, NK, and ADMA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/18/2026ADMAADMA Biologics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)6/17/2026AUTLAutolus Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/11/2026STROSutro Biopharma Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$50.006/10/2026ADMAADMA Biologics Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageStrong-Buy ➝ Outperform$21.006/10/2026ADMAADMA Biologics Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeModerate Buy$21.005/29/2026AUTLAutolus Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/28/2026STROSutro Biopharma BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$56.005/28/2026STROSutro Biopharma BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$56.005/26/2026ADMAADMA Biologics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell5/15/2026STROSutro Biopharma Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetOutperform$38.00 ➝ $43.005/15/2026STROSutro Biopharma HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$28.00 ➝ $50.00(Data available from 6/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADMAADMA Biologics$509.86M3.95$0.68 per share12.70$2.01 per share4.32AUTLAutolus Therapeutics$92.62M4.77N/AN/A$0.67 per share2.48GRTSGritstone bio$496K7.05N/AN/A$0.54 per share0.06NKNantKwest$40K19,080.70N/AN/A$1.23 per share5.67STROSutro Biopharma$99.61M4.86N/AN/A($15.43) per share-1.89Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADMAADMA Biologics$146.93M$0.6812.789.24N/A32.43%39.98%28.08%8/5/2026 (Estimated)AUTLAutolus Therapeutics-$287.53M-$1.09N/AN/AN/A-311.98%-128.59%-46.25%8/11/2026 (Estimated)GRTSGritstone bio-$138.49M-$1.24N/AN/AN/A-910.50%-328.51%-82.53%N/ANKNantKwest-$65.79M-$0.70N/AN/AN/A-76,658.58%-56.06%-46.93%N/ASTROSutro Biopharma-$191.09M-$11.04N/AN/AN/A-154.21%N/A-69.20%8/6/2026 (Estimated)Latest STRO, GRTS, AUTL, NK, and ADMA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026AUTLAutolus Therapeutics-$0.29-$0.27+$0.02-$0.27$26.27 million$26.22 million5/14/2026Q1 2026STROSutro Biopharma-$2.7363-$2.94-$0.2037-$2.94$8.89 million$14.52 million5/6/2026Q1 2026ADMAADMA Biologics$0.1933$0.19-$0.0033$0.19$139.98 million$114.49 million3/27/2026Q4 2025AUTLAutolus Therapeutics-$0.27-$0.34-$0.07-$0.34$23.92 million$24.29 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthADMAADMA BiologicsN/AN/AN/AN/AN/AAUTLAutolus TherapeuticsN/AN/AN/AN/AN/AGRTSGritstone bioN/AN/AN/AN/AN/ANKNantKwestN/AN/AN/AN/AN/ASTROSutro BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADMAADMA Biologics0.516.953.93AUTLAutolus TherapeuticsN/A5.805.28GRTSGritstone bio1.832.542.54NKNantKwestN/A4.744.74STROSutro BiopharmaN/A3.123.12Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADMAADMA Biologics75.68%AUTLAutolus Therapeutics72.83%GRTSGritstone bio48.46%NKNantKwest9.38%STROSutro Biopharma96.99%Insider OwnershipCompanyInsider OwnershipADMAADMA Biologics3.90%AUTLAutolus Therapeutics25.70%GRTSGritstone bio4.61%NKNantKwest71.73%STROSutro Biopharma3.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADMAADMA Biologics530231.77 million222.73 millionOptionableAUTLAutolus Therapeutics330266.16 million197.75 millionOptionableGRTSGritstone bio190108.57 million111.84 millionNo DataNKNantKwest160109.35 millionN/ANot OptionableSTROSutro Biopharma24016.57 million15.59 millionOptionableSTRO, GRTS, AUTL, NK, and ADMA HeadlinesRecent News About These CompaniesSutro Biopharma, Inc. (NASDAQ:STRO) Short Interest UpdateJune 15, 2026 | americanbankingnews.comWall Street Zen Downgrades Sutro Biopharma (NASDAQ:STRO) to SellJune 14, 2026 | americanbankingnews.comNews Flash: Analysts Just Made A Massive Upgrade To Their Sutro Biopharma, Inc. (NASDAQ:STRO) ForecastsMay 28, 2026 | finance.yahoo.comUS$47.10 - That's What Analysts Think Sutro Biopharma, Inc. (NASDAQ:STRO) Is Worth After These ResultsMay 17, 2026 | finance.yahoo.comWedbush upgrades Sutro Biopharma (STRO)May 16, 2026 | msn.comSutro Biopharma Reports First Quarter 2026 Financial Results and Business HighlightsMay 14, 2026 | globenewswire.comCitizens Lifts PT on Sutro Biopharma (STRO) on Its Pipeline and Lead ProgramMay 1, 2026 | insidermonkey.comMizuho initiates coverage of Sutro Biopharma (STRO) with outperform recommendationMay 1, 2026 | msn.comSutro Biopharma: Recycling Past Data Ahead Of The Readout, SellMay 1, 2026 | seekingalpha.comHere is Why Sutro Biopharma (STRO) is One of the Tiny Stocks That Are On Fire Right NowApril 29, 2026 | finance.yahoo.comSutro Biopharma, Inc. (STRO) Presents at AACR Annual Meeting 2026 - SlideshowApril 24, 2026 | seekingalpha.comSutro Biopharma Presents Promising Preclinical Data Across its Pipeline of Next-Generation Single and Dual-Payload ADC Programs at AACR 2026April 19, 2026 | markets.businessinsider.comSutro Biopharma Reports Promising Preclinical Data for Next-Generation ADCs STRO-004, STRO-006, and STRO-227 at AACR Annual Meeting 2026April 19, 2026 | quiverquant.comQSutro Biopharma (NASDAQ:STRO) Trading 10.4% Higher on Analyst UpgradeApril 18, 2026 | defenseworld.netDSutro Biopharma (STRO) price target decreased by 21.62% to 29.58April 9, 2026 | msn.comSutro Biopharma (STRO) Moves 7.4% Higher: Will This Strength Last?April 8, 2026 | zacks.comLeerink Partners initiates coverage of Sutro Biopharma (STRO) with outperform recommendationApril 8, 2026 | msn.comSutro Biopharma (STRO) price target increased by 13.85% to 37.74March 27, 2026 | msn.comWells Fargo upgrades Sutro Biopharma (STRO)March 25, 2026 | msn.comHC Wainwright & Co. upgrades Sutro Biopharma (STRO)March 25, 2026 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesWill the SpaceX IPO Put These 5 Public Space Stocks Into a Higher Orbit?By Ryan Hasson | June 2, 2026Drone Stocks Soar As Pentagon Considers Funding, Including a Trump-Linked NameBy Leo Miller | June 1, 20263 Stocks With Fresh Catalysts to Watch Before July 4By Chris Markoch | June 8, 2026SpaceX Rings the Bell and Shatters Every RecordBy Jeffrey Neal Johnson | June 12, 20263 Up-and-Coming Stocks That Could Be the Next NVIDIABy Chris Markoch | June 1, 2026STRO, GRTS, AUTL, NK, and ADMA Company DescriptionsADMA Biologics NASDAQ:ADMA$8.69 +0.12 (+1.40%) As of 04:00 PM EasternADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.Autolus Therapeutics NASDAQ:AUTL$1.66 +0.17 (+11.41%) As of 04:00 PM EasternAutolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.Gritstone bio NASDAQ:GRTSGritstone bio, Inc., a clinical-stage biotechnology company, engages in developing vaccine-based immunotherapy candidates against cancer and infectious diseases. Its primary product candidate is GRANITE, an individualized immunotherapy candidate, which is in Phase 2/3 clinical trials for the treatment of microsatellite stable colorectal cancers; and has completed Phase 1/2 clinical trials for treating solid tumors. The company is also developing SLATE, an off-the-shelf immunotherapy candidate, which is in Phase 2 clinical trials for the treatment of metastatic solid tumors. In addition, it develops CORAL, a COVID-19 vaccine program; and a therapeutic vaccine candidate that is in Phase 1 clinical trials designed to treat and cure human immunodeficiency virus (HIV) infection. Gritstone bio, Inc. has a strategic collaboration with bluebird bio, Inc.; collaboration agreement with Gilead Sciences, Inc.; and license agreement with Genevant Sciences GmbH. The company was formerly known as Gritstone Oncology, Inc. and changed its name to Gritstone bio, Inc. in May 2021. Gritstone bio, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.NantKwest NASDAQ:NKNantKwest, Inc., a clinical-stage immunotherapy company, develops immunotherapeutic treatments for cancer and viral infectious diseases in the United States. The company develops activated natural killer (aNK) cell, a natural killer cell-line and genetically modified derivative capable of killing cancer and virally infected cells; and Nant cancer vaccine, a personalized therapy that utilizes its off-the-shelf natural killer cells. It is also developing high-affinity natural killer (haNK) product candidates primarily for the treatment of various cancers; and tank and t-haNK product candidates to treat solid tumors. NantKwest, Inc. has a co-development agreement with Altor BioScience, LLC to collaborate on the development of therapeutic applications combining the company's proprietary natural killer cells with Altor's N-801 and/or N-803 products; collaboration with Be The Match BioTherapies for the development of cell therapy to prevent COVID-19 deaths; and strategic alliance with Immunitybio. It also has a collaboration with CBR Systems, Inc. to develop a COVID-19 treatment leveraging newborn stem cells. The company was formerly known as Conkwest, Inc. and changed its name to NantKwest, Inc. in July 2015. NantKwest, Inc. was founded in 2002 and is headquartered in San Diego, California.Sutro Biopharma NASDAQ:STRO$29.19 -2.36 (-7.48%) As of 04:00 PM EasternSutro Biopharma, Inc. operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer. The company's pre-clinical product candidates include STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors and hematological cancers; and STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including cervical, lung, and breast cancer. Sutro Biopharma, Inc. has collaboration and license agreements with Merck Sharp & Dohme Corporation to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; EMD Serono to develop ADCs for multiple cancer targets; and Astellas Pharma Inc. to develop immunostimulatory ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Oracle’s Sell-Off Looks More Like a Mispricing Than a Warning These AI Stocks Have Insider Selling, But Buyers Still Have a Reason to Stay Apple’s Intel Deal Arrives at the Right Time for Its Stock Micron’s Sudden Plunge May Be an AI Buying Chance Amazon’s Pullback Deepens as a New FTC Risk Hits the Stock The Biotech Sector Looks Ready for a Multi-Year Breakout—Here's What to Watch. How Does D-Wave's New Simulator Change the Quantum Computing Landscape? How Intel Is Packaging the Future of American Chips Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
